文献速递传染病防控与疫情报告免疫规划

高滴度O1 Manisa口蹄疫疫苗对牛抵抗北非O/ME-SA/Ind-2001谱系田间病毒异源攻击的效力

Efficacy of a high potency O1 Manisa foot-and-mouth disease vaccine in cattle against heterologous challenge with a field virus from the O/ME-SA/Ind-2001 lineage collected in North Africa.
PubMed 文献 · Vaccine · 2017-04-07

研究评估高滴度O1 Manisa口蹄疫疫苗对牛抵抗北非O/ME-SA/Ind-2001谱系田间病毒O/ALG/3/2014异源攻击的体内效力。三组各5头牛按欧洲药典指南接种不同剂量疫苗,接种后21天舌部接种病毒攻击。最低剂量组全部发生全身性口蹄疫,1/4剂量组1头、全剂量组2头发生全身性疾病,异源效力约为3.5 PD50/剂。

要点

  • 高滴度O1 Manisa疫苗对异源田间病毒的效力约为3.5 PD50/剂。
  • 接种最低剂量(1/16)的牛全部出现全身性口蹄疫。
  • 1/4剂量组1头、全剂量组2头牛出现全身性疾病。

核心结论

  • 高滴度O1 Manisa疫苗的异源效力约为3.5 PD50/剂。
  • 数据支持在口蹄疫地方性流行区(如北非)使用O1 Manisa疫苗进行口蹄疫控制。
  • 研究激发进一步评估其他候选疫苗(或多价组合),以用于无口蹄疫地区的紧急用途。

研究设计与样本

  • 研究将三组各5头牛按欧洲药典指南接种O1 Manisa疫苗(同源效力≥6PD50/剂),接种后21天经舌部接种O/ALG/3/2014田间病毒进行攻击。
  • 选择该广泛可用疫苗是因为体外疫苗匹配结果无法确定其是否具有保护性。

主要发现

  • 接种最低剂量(1/16)疫苗的所有牛均发生全身性口蹄疫,定义为足部水疱性病变。
  • 接种1/4剂量疫苗的牛中有1头发生全身性疾病。
  • 接种全剂量疫苗的牛中有2头发生全身性疾病。
  • 异源效力约为3.5 PD50/剂。

临床怎么用

  • 作者认为数据支持在口蹄疫地方性流行区(如北非)使用O1 Manisa疫苗进行口蹄疫控制。
  • 作者建议进一步研究评估其他候选疫苗(或多价组合),以用于无口蹄疫地区的紧急用途。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outbreaks of foot-and-mouth disease (FMD) in North Africa (2013) and the Gulf States (2013) of the Middle East have been caused by a FMD viral lineage (O/ME-SA/Ind-2001) that was before 2013 restricted to the Indian Sub-continent. This study was undertaken to assess the in vivo efficacy of a FMD virus emergency vaccine type O1 Manisa against heterologous challenge with a representative field virus (O/ALG/3/2014) from this emerging lineage. This widely available vaccine was selected since in vitro vaccine-matching results gave inconclusive results as to whether or not it would be protective. Three groups of five cattle were vaccinated with O1 Manisa (homologous potency ≥6PD50/dose) using study guidelines outlined in the European Pharmacopeia, and challenged at 21days post-vaccination by tongue inoculation. All animals that were vaccinated with the lowest dose (1/16) of vaccine developed generalised FMD, defined as vesicular lesions at the feet. One animal vaccinated with a 1/4 dose of the vaccine also developed generalised disease, as did two animals vaccinated with the full dose of vaccine. These results indicate that the heterologous potency of this high potency O1 Manisa vaccine was approximately 3.5 PD50/dose. These data support the use of the O1 Manisa vaccine for FMD control in areas where FMDV is endemic e.g. North Africa, and motivate further studies to evaluate other vaccine candidates (or multivalent combinations) that might be potentially used for emergency purposes in FMD-free settings.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fishbourne E, Ludi AB, Wilsden G, et al. Efficacy of a high potency O1 Manisa foot-and-mouth disease vaccine in cattle against heterologous challenge with a field virus from the O/ME-SA/Ind-2001 lineage collected in North Africa. Vaccine. 2017. PMID: 28396208. doi:10.1016/j.vaccine.2017.02.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。